New antibody combo aims to boost immune attack on Hard-to-Treat cancers
NCT ID NCT05537740
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 30 times
Summary
This early-stage trial tests a new antibody, BAY 3375968, designed to help the immune system fight advanced solid tumors. It works by reducing regulatory T cells that can suppress immune activity. The study will test the drug alone and combined with pembrolizumab in about 129 people with cancers like lung, breast, head and neck, stomach, or melanoma. The main goals are to check safety, find the best dose, and see how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Antwerp University Hospital | Oncology Department
Antwerp, 2650, Belgium
-
CHU de Liège
Liège, 4000, Belgium
-
Centre Oscar Lambret - Service Oncologie
Lille, Hauts-de-France, 59000, France
-
Clinica Universidad De Navarra | Madrid | Oncologia
Madrid, 28027, Spain
-
Clinica Universidad De Navarra | Pamplona | Oncologia
Pamplona, Navarre, 31008, Spain
-
Ghent University Hospital | Drug Research Unit Department
Ghent, 9000, Belgium
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510000, China
-
Hospital Universitari Vall D Hebron | Oncologia Medica
Barcelona, 08035, Spain
-
Hospital Universitario Hm Sanchinarro | Oncologia Medica
Madrid, 28050, Spain
-
Institut Bergonie - Unicancer Nouvelle Aquitaine - Service Oncologie medicale
Bordeaux, New Aquitaine, 33000, France
-
Institut Gustave Roussy - Departement d'Innovation Therapeutique et d'Essais Precoces (DITEP)
Villejuif, Île-de-France Region, 94805, France
-
Institut de Cancerologie Ouest - Saint Herblain - Oncologie medicale
Saint-Herblain, Pays de la Loire Region, 44800, France
-
Jilin Cancer Hospital
Changchun, Jilin, 130000, China
-
LinYi Cancer Hospital (Linyi Tumor Hospital)
Linyi, 276001, China
-
National Cancer Center Singapore - Oncology Department
Singapore, 168583, Singapore
-
National University Hospital Medical Centre
Singapore, 119074, Singapore
-
OncoCare Cancer Centre | Gleneagles Medical Centre
Singapore, 258499, Singapore
-
Princess Margaret Cancer Centre - Oncology Department
Toronto, Ontario, M5G 2C4, Canada
-
Royal Marsden NHS Trust (Surrey)
Sutton, Surrey, SM2 5PT, United Kingdom
-
START | San Antonio
San Antonio, Texas, 78229, United States
-
South Texas Accelerated Research Therapeutics | START Rocky Mountain Region
West Valley City, Utah, 84119, United States
-
The Christie NHS Foundation Trust - Christie Hospital
Manchester, Greater Manchester, M204BX, United Kingdom
-
The Sixth Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510655, China
-
The University of Chicago Medical Center - Hyde Park - Hematology & Oncology
Chicago, Illinois, 60637, United States
-
UNC Hospitals - UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27514, United States
-
Universitair Ziekenhuis Leuven | Gasthuisberg Campus - General Medical Oncology
Leuven, 3000, Belgium
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BAY 3375968 (also called Lanerkitug) and pembrolizumab
What this could lead to
If this works, it could offer a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early (Phase 1) trial with only 129 participants. The main goal is safety and dosing, not yet proving effectiveness. Side effects are unknown, and the drug may not work in humans as it did in animals.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.